Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results